Literature DB >> 2782755

Prognosis of chronic obstructive pulmonary disease: the Dutch experience.

D S Postma1, H J Sluiter.   

Abstract

This article summarizes the Dutch experience with prognosis in three groups of patient with chronic obstructive pulmonary disease. (1) 129 patients with severe chronic airflow obstruction (mean FEV1 1,880 ml, range 1,200 to 2,500 ml); (3) 81 patients out of group 2 with decline in FEV1 over time, without oral corticosteroids. It is clear that, at least in the presence of regular therapy, next to cessation of smoking, a higher reversibility of airflow obstruction and lower degree of airway hyperreactivity are important predictors of a slower decline in FEV1. In our opinion these findings point to the urgency for clinicians to change the nihilistic attitude towards patients with CAO, in that both smoking cessation and an early therapy directed at the reversible part of airflow obstruction and airway hyperreactivity may be able to prevent deterioration. Future studies have to show whether long-term, ongoing therapy with corticosteroids may even change the progression and survival in far advanced disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2782755     DOI: 10.1164/ajrccm/140.3_Pt_2.S100

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

Review 1.  Lung transplantation and lung volume reduction surgery versus transplantation in chronic obstructive pulmonary disease.

Authors:  Namrata Patel; Malcolm DeCamp; Gerard J Criner
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

2.  Evidence for two unlinked loci regulating total serum IgE levels.

Authors:  J Xu; R C Levitt; C I Panhuysen; D S Postma; E W Taylor; P J Amelung; K J Holroyd; E R Bleecker; D A Meyers
Journal:  Am J Hum Genet       Date:  1995-08       Impact factor: 11.025

3.  Reversible bronchial obstruction and disease-related health status in COPD.

Authors:  R A Incalzi; V Bellia; S Maggi; C Imperiale; O Capparella; R Pistelli; V Grassi
Journal:  Qual Life Res       Date:  2002-09       Impact factor: 4.147

4.  Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study.

Authors:  D M Mannino; A S Buist; T L Petty; P L Enright; S C Redd
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 5.  The efficacy and safety of cilomilast in COPD.

Authors:  Stephen Rennard; Katharine Knobil; Klaus F Rabe; Andrea Morris; Neil Schachter; Nicholas Locantore; Walter G Canonica; Yuanjue Zhu; Frank Barnhart
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients.

Authors:  T J Crowley; M J Macdonald; M I Walter
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

Review 7.  Systematic review of the evidence relating FEV1 decline to giving up smoking.

Authors:  Peter N Lee; John S Fry
Journal:  BMC Med       Date:  2010-12-14       Impact factor: 8.775

8.  Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study.

Authors:  Pere Almagro; Pablo Martinez-Camblor; Joan B Soriano; Jose M Marin; Inmaculada Alfageme; Ciro Casanova; Cristobal Esteban; Juan J Soler-Cataluña; Juan P de-Torres; Bartolome R Celli; Marc Miravitlles
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

Review 9.  Chronic obstructive pulmonary disease.

Authors:  J M Madison; R S Irwin
Journal:  Lancet       Date:  1998-08-08       Impact factor: 79.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.